A real-world analysis builds on trial evidence that ibrutinib is most effective for patients with mantle cell lymphoma (MCL) at first relapse. The Bruton tyrosine kinase inhibitor is now widely available in the relapsed/refractory MCL setting, but there remains no consensus on the optimal timing of the agent. A pooled trial analysis previously showed a ...
Ibrutinib effective at first MCL relapse in a real-world study
By Dave Levitan
4 Mar 2021